Krystal Biotech, Inc.
Krystal Biotech, Inc. (KRYS) Revenue
Annual & quarterly revenue history · segment & region breakdown
KRYS · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsKrystal Biotech, Inc. trailing twelve-month (TTM) revenue is $0.42B, an increase of 33.94% year-over-year from $0.39B in FY2025.
Revenue trend
2025 – 2016 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.39B | +$0.10B | +33.94% |
| 2024-12-31 | $0.29B | +$0.24B | +473.02% |
| 2023-12-31 | $0.05B | +$0.05B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | -$0.00B | -100.00% |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare KRYS revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Krystal Biotech, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Krystal Biotech, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Krystal Biotech, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
KRYS revenue · 4 questionsKRYS's trailing twelve-month (TTM) revenue is $0.42B. That is an increase of 33.94% year-over-year from $0.39B in FY2025.
▸ Source: FMP · Krystal Biotech, Inc. SEC filings · GAAP · Krystal Biotech, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026